BMS Extends Lonza Contract

Bristol-Myers Squibb (BMS) says it has agreed to extend a supply agreement with Lonza, in which Lonza will manufacture BMS’s biologic rheumatoid arthritis drug Orencia until 2014. Orencia was approved by FDA in 2005 and launched in the U.S. in February 2006. The product generated sales of $32 million in the final quarter of 2006. Lonza will produce the product at its Portsmouth, NH facility. Separately, Lonza says it has granted UCB a non-exclusive license to its glutamine synthetase (GS) gene expression system for manufacturing therapeutic recombinant...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers